{
    "clinical_study": {
        "@rank": "156353", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "ESBA1008 solution Day 0 (Dose A) and Day 28 (Dose B), or Ranibizumab Day 0 and Day 28, based on randomization"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "ESBA1008 solution Day 0 (Dose D) and Day 28 (Dose B), or Ranibizumab Day 0 and Day 28, based on randomization"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "ESBA1008 solution Day 0 (Dose C) and Day 28 (Dose B), or Ranibizumab Day 0 and Day 28, based on randomization"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "ESBA1008 solution Day 0 (Dose E) and Day 28 (Dose B), or Ranibizumab Day 0 and Day 28, based on randomization"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a\n      microvolume injection or infusion on retinal function and morphology in subjects with\n      exudative age-related macular degeneration (AMD)."
        }, 
        "brief_title": "ESBA1008 Microvolume Study", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Exudative Age-Related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Wet Macular Degeneration"
            ]
        }, 
        "detailed_description": {
            "textblock": "This 4-cohort study will be conducted in 2 stages. In Stage 1, subjects will be randomized\n      to receive 2 ESBA1008 injections (Cohort 1), 1 ESBA1008 infusion and 1 injection (Cohort 2),\n      or 2 LUCENTIS injections (Cohort 1 and 2).  Stage 2 will be conducted similarly with a\n      different dosing level for ESBA1008 (Cohort 3 and 4). After the Day 28 visit (all cohorts),\n      subjects will return for follow up visits at Day 42 and Day 56."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Sign informed consent document;\n\n          -  Able to make the required study visits and follow instructions;\n\n          -  Age-related macular degeneration in the study eye;\n\n          -  Visual acuity within protocol-specified range;\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Both eyes: Any active infection or inflammation;\n\n          -  Study eye: Any treatment for exudative age-related macular degeneration (AMD) other\n             than vitamin supplements;\n\n          -  Study eye: Any current or history of macular or retinal disease;\n\n          -  Study eye: Any concurrent intraocular condition such as cataract or diabetic\n             retinopathy that, in the opinion of the Investigator, could either require medical or\n             surgical intervention during the course of the study to prevent or treat visual loss;\n\n          -  Study eye: Other ocular conditions or diseases that, in the opinion of the\n             Investigator, could compromise visual acuity;\n\n          -  Study Eye: Uncontrolled glaucoma;\n\n          -  History of a medical condition that, in the opinion of the Investigator, would\n             preclude scheduled study visits, completion of the study, or a safe administration of\n             investigational product;\n\n          -  Women of childbearing potential who are lactating, pregnant, planning to become\n             pregnant, or not using adequate birth control methods for the duration of the study;\n\n          -  Intraocular surgery within 3 months of baseline;\n\n          -  Study eye: Any history or current evidence of retinal angiomatous proliferation (RAP)\n             lesions based on clinical exam;\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01849692", 
            "org_study_id": "C-13-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3", 
                    "Cohort 4"
                ], 
                "description": "Dose A, B, C: single intravitreal injection; Dose D, E: infusion", 
                "intervention_name": "ESBA1008 solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3", 
                    "Cohort 4"
                ], 
                "description": "0.5 mg/50 \u03bcL, single intravitreal injection", 
                "intervention_name": "Ranibizumab", 
                "intervention_type": "Drug", 
                "other_name": "LUCENTIS"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Exudative Age-Related Macular Degeneration", 
            "Wet AMD", 
            "Choroidal neovascularization (CNV)", 
            "Vascular endothelial growth factor (VEGF)"
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Prospective, Two-Staged, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects With Exudative Age-Related Macular Degeneration", 
        "overall_contact": {
            "email": "alcon.medinfo@alcon.com", 
            "last_name": "Alcon Call Center", 
            "phone": "1-888-451-3937"
        }, 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Susan Yanni, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A subject will be considered a responder if at least 3 out of the following 4 criteria are fulfilled in comparison to baseline:\nProtocol-specified letter gain in BCVA at Day 14\nProtocol-specified letter gain in BCVA at Day 28\nProtocol-specified micron loss in CSFT at Day 14\nProtocol-specified micron loss in CSFT at Day 28", 
            "measure": "Response based upon central subfield thickness (CSFT) and best-corrected visual acuity (BCVA) outcomes at Day 14 and Day 28", 
            "safety_issue": "No", 
            "time_frame": "Baseline, up to Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01849692"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "As measured by Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing", 
                "measure": "Change from baseline in Best Corrected Visual Acuity (BCVA)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, up to Day 56"
            }, 
            {
                "description": "As measured by Spectral-Domain Optical Coherence Tomography (SD-OCT)", 
                "measure": "Change from baseline in Central Subfield Thickness (CSFT)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, up to Day 56"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}